Our proprietary immunotherapy, ValloVax aims to Starve the Tumor by training your immune system to target the tumor associated blood vessels.
About Us
Batu Biologics is an immune oncology Company based out of San Diego, California. We were founded in December of 2013 to investigate the parallels between placental and tumor angiogenesis with the goal of discovering an effective natural treatment for cancer. Currently, Batu Biologics is focused on developing the “ValloVax™” platform, an allogeneic and universal donor cellular vaccine designed to stimulate a targeted immune response against several tumor angiogenesis antigens for the treatment of a wide array of cancers.
Activites
Clinical Development
of ValloVax™
Research of cancer
immunotherapy
IP expansion and
licensing opportunities
Optimization of Therapeutic
Vaccine Immunogenicity
Academic Collaborations
Where the research stands today
Batu Biologics has received FDA clearance of its Investigational New Drug Application for ValloVax allowing the Company to proceed with a Phase I study to assess the safety and immunogenicity in patients with metastatic Non Small Cell Lung Cancer. The Company has preclinical and clinical proof of concept and is currently raising funds to deploy the Phase I study at the John Wayne Cancer Institute before the end of this year. To find out how you can help, please subscribe to our newsletter below.
Our Philosophy
At Batu Biologics we believe the most powerful tools to fight disease lie within your body, the key is to unleash them. We can envision a future where cancer patients do not have to choose between life saving medication and forgoing treatment to maintain their quality of life. There is a need for less toxic and more effective therapeutic options that train the body’s immune system to recognize and fight cancer.
OUR VIDEO
Batu Biologics News
17 October 2018
Batu Biologics Recruits Vice President of Precision Oncology
Batu Biologics Recruits Dr. Vijay Mahant as the Vice President of Precision Oncology to Oversee the Personalization of ValloVax Immunogenicity Dr. Mahant to assist with the development of screening cr
24 September 2018
Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog
Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog Clinical Stage Immuno-Oncology Company Releases Media Platform to Provide Background Information on Lead Technology Toda
20 August 2018
Batu Biologics Identifies Gene Types Associated with Response to ValloVax
Batu Biologics Identifies Gene Types Associated with Response to ValloVax Preliminary Evaluation of Over 100 Patients Treated with Cancer Blood Vessel Targeting Immunotherapy Reveals Gene Association
26 July 2018
Batu Biologics files Right to Try Patent
Batu Biologics Files Patent on Patient Selection for Right to Try Law Clinical Stage Immunotherapy Company Creates System of Selecting Patients for Optimized Outcome under President Donald Trump’s R
12 June 2018
Batu Biologics Recruits Nobel Prize Winner Bruce Beutler
Nobel Prize Winning Immunologist Joins Batu Biologics in Quest to “Starve the Tumor” Clinical Stage Immuno-Oncology Company Recruits Pioneer of Innate Immunity to Scientific Advisory Board Batu Bi
31 May 2018
Batu Biologics Releases Shareholder Letter
Company discusses the clinical progress of the ValloVax Therapeutic Vaccine at the CHIPSA Hospital Samuel C. Wagner, President and CEO of Batu Biologics, has issued the following letter to the shareho
24 March 2018
Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board
Pioneer of Tumor Immunotherapy Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board Former President of the Society for Immunotherapy of Cancer to Assist Company in
16 March 2018
Batu Biologics CEO to Moderate Congressional Immunotherapy Symposium
Batu Biologics Chief Executive Officer Samuel Wagner to Moderate Congressional Immunotherapy Symposium Congressional Candidate to Hear Concerns of Industry Leaders in Health Care Innovations Batu Biol
2 March 2018
Batu Biologics CEO Selected for Lyfebulb Oncology Award
Batu Biologics CEO Selected as Finalist for Lyfebulb-Helsinn Innovation Summit and Award For Oncology Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Awa
25 December 2017
Batu Biologics Raises $1.3 Million in Equity Crowdfunding
Batu Biologics Successfully Completes $1.3 Million #Starvethetumor Equity Crowdfunding Campaign Company Intends to Aggressively Pursue Clinical Development of Angiogenesis Targeting Immunotherapy Prod
